Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiotherapy technique aims to cut prostate cancer treatment side effects

NCT ID NCT07245745

Symptom relief Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares adaptive radiotherapy (ART) with conventional radiotherapy in 188 men with prostate cancer. ART adjusts the radiation beam daily to account for changes in organ position, potentially reducing digestive and urinary side effects. Patients will report their symptoms through questionnaires and a mobile app. The goal is to see if ART leads to fewer and shorter-lasting side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (adaptive vs. conventional)
What this could lead to
If successful, adaptive radiotherapy could become a standard approach to reduce digestive and urinary side effects during prostate cancer treatment.
What could go wrong
This is a non-randomized, observational study with only 188 participants, so results may not apply broadly. The adaptive technique may not significantly reduce side effects compared to conventional methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 188 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with prostate cancer referred for curative-intent radiotherapy * Male patients ≥ 18 years old * ECOG performance status 0-1 * Patients willing to use an e-health application * Patients capable of using an e-health application * Proficient in French, English, or Dutch * No prior history of treatment for rectal or bladder cancer * No prior history of pelvic radiotherapy Exclusion Criteria: * Cognitive impairment * ECOG ≥ 2 * History of treatment for rectal or bladder cancer * History of pelvic radiotherapy * No access to the Noona application on a smartphone or computer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cliniques universitaires Saint-Luc

    RECRUITING

    Brussels, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.